# Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma

> **NCT03880123** · PHASE1 · WITHDRAWN · sponsor: **Matthew Ingham**

## Conditions studied

- Liposarcoma
- Malignant Peripheral Nerve Sheath Tumors
- Alveolar Soft Part Sarcoma
- Ewing Sarcoma
- Sarcoma

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Ixazomib

## Key facts

- **NCT ID:** NCT03880123
- **Lead sponsor:** Matthew Ingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-11
- **Primary completion:** 2020-11-24
- **Final completion:** 2020-11-24
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study will not proceed, no participants enrolled.
- **Last updated:** 2020-11-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03880123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03880123, "Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03880123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*